Merck's Keytruda® with chemoradiotherapy significantly improved overall survival for high-risk locally advanced cervical cancer patients in the KEYNOTE-A18 trial.
Merck's Keytruda® in combination with chemoradiotherapy (CRT) has significantly improved overall survival (OS) for patients with newly diagnosed high-risk locally advanced cervical cancer, according to results from the Phase 3 KEYNOTE-A18 trial. The combination showed a statistically significant and clinically meaningful improvement in OS versus CRT alone. No new safety signals were identified.
March 15, 2024
6 Articles